VIR (Vir Biotechnology) NonCurrent Deferred Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIR Vir Biotechnology Inc VIR
52 GF Score
Price $9.50
GF Value $42.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Vir Biotechnology NonCurrent Deferred Liabilities?

Vir Biotechnology VIR +0.96% 52 NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates VIR with a GF Score™ of 52/100 and a GF Value™ of $42.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Vir Biotechnology's non-current deferred liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

Vir Biotechnology NonCurrent Deferred Liabilities Related Terms

Vir Biotechnology NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Vir Biotechnology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vir Biotechnology NonCurrent Deferred Liabilities Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only 22.25 53.21 0.00 0.00 0.00

Vir Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 9.43 0.00 0.00 0.00
VIR
52GF Score
Vir Biotechnology Inc VIR
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Vir Biotechnology (VIR) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Vir Biotechnology and its competitors.
Is Vir Biotechnology's NonCurrent Deferred Liabilities too high?
Vir Biotechnology's current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Vir Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's NonCurrent Deferred Liabilities compare to AVBP and XNCR?
Vir Biotechnology's NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.20, compared to a current price of $9.50 — trading 77.5% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vir Biotechnology (VIR) Overvalued in 2026?

Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued. The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.20. GuruFocus considers Vir Biotechnology to be Possible Value Trap.

Key valuation signals for VIR:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $42.20 vs. price of $9.50 (77.5% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vir Biotechnology Business Description

Address 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score

Get the complete analysis for VIR

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.50
Price
$42.20
GF Value